Literature DB >> 25485492

PARP inhibitors target ATM+p53-defective gastric cancer.

Nicola J Curtin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25485492      PMCID： PMC4615070          DOI： 10.4161/15384101.2014.948787

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Authors:  Eiji Kubota; Christopher T Williamson; Ruiqiong Ye; Anifat Elegbede; Lars Peterson; Susan P Lees-Miller; D Gwyn Bebb
Journal:  Cell Cycle       Date:  2014-05-19       Impact factor: 4.534

2.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

Authors:  Victoria J Weston; Ceri E Oldreive; Anna Skowronska; David G Oscier; Guy Pratt; Martin J S Dyer; Graeme Smith; Judy E Powell; Zbigniew Rudzki; Pamela Kearns; Paul A H Moss; A Malcolm R Taylor; Tatjana Stankovic
Journal:  Blood       Date:  2010-08-25       Impact factor: 22.113

3.  Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.

Authors:  Jin Won Kim; Seock-Ah Im; Min A Kim; Hyun Jin Cho; Dae Won Lee; Kyung-Hun Lee; Tae-Yong Kim; Sae-Won Han; Do-Youn Oh; Hyuk-Joon Lee; Tae-You Kim; Han-Kwang Yang; Woo Ho Kim; Yung-Jue Bang
Journal:  Int J Cancer       Date:  2013-09-17       Impact factor: 7.396

4.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

Authors:  Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

5.  Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.

Authors:  Chris T Williamson; Eiji Kubota; Jeffrey D Hamill; Alexander Klimowicz; Ruiqiong Ye; Huong Muzik; Michelle Dean; LiRen Tu; David Gilley; Anthony M Magliocco; Bruce C McKay; D Gwyn Bebb; Susan P Lees-Miller
Journal:  EMBO Mol Med       Date:  2012-03-13       Impact factor: 12.137

6.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.